Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05780931
Other study ID # C4099-P
Secondary ID I21RX004099-01A1
Status Not yet recruiting
Phase
First received
Last updated
Start date July 1, 2024
Est. completion date June 30, 2026

Study information

Verified date January 2024
Source VA Office of Research and Development
Contact Jay Hegde, PhD
Phone (706) 733-0188
Email JHEGDE@augusta.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will help develop new methods of rehabilitating Veterans with vision loss due to Age-related macular degeneration.


Description:

The purpose of this research study is to develop new and improved methods of helping vision-impaired Veterans see better by using hands as "seeing eyes". This study will focus on Veterans with a common form of eye disease called age-related macular degeneration that affects older individuals.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date June 30, 2026
Est. primary completion date December 30, 2025
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: 1. The subject is a Veteran. 2. The subject is 50 years of age. 3. The subject has best-corrected visual acuity (BCVA) of 20/40 or worse in each eye, as determined by the standard CNVAMC optometric tests. 4. The subject has visual field deficit of 10O in either eye as determined by the Octopus 900 perimetry (Haag-Streit Diagnostics, Haag-Streit USA, Mason, OH) administered by CNVAMC. (When the deficit/s are binocular, they do not necessarily have to be in binocularly corresponding positions.) 5. The subject has received a formal clinical diagnosis of age-related macular degeneration (AMD) in one or both eyes (binocular AMD does not necessarily have to be in binocularly corresponding positions)7,8,56. 6. The subject has visual deficit in either eye (wavy lines and/or missing/darkened areas on the grid) determined by the standard Amsler Grid Test7,8,56. 7. The subject has not yet started any rehabilitative treatment for AMD-related vision loss. 8. Both eyes of the subject are otherwise age-appropriately stable, and neither eye has any other visual defects, as determined by the standard CNVAMC ophthalmological examination. 9. The subject must be able to understand the nature and individual consequences of the study. 10. The subject must be able to provide signed and dated informed consent before start of any participation in the study procedures. 11. Women with childbearing potential must test negative for pregnancy using a standard urine test prior to participating in each functional magnetic resonance imaging (fMRI) procedure. (This exclusion criterion is mandated by the Augusta University Institutional Review Board [AU IRB], which also serves as the IRB of record of the CNVAMC. It is intended as an extra precautionary measure to help ensure the health and safety of this vulnerable population. The proposed study will comply with this requirement.) Exclusion Criteria: 1. According to the patient's VA clinical records, the patient has one or more clinically diagnosed neurological disorder. 2. According to the patient's VA clinical records, the patient has one or more clinically diagnosed cognitive deficits. 3. According to the patient's VA clinical records, the patient has been clinically diagnosed with a psychiatric disorder that would make it unduly uncomfortable or otherwise clinically inadvisable for the subject to participate in the study. 4. According to the patient's VA clinical records, according to the patient, or both, the patient has motor disorder/s that would make it unduly uncomfortable or otherwise clinically inadvisable for the subject to participate in the study. 5. According to the patient's VA clinical records, according to the patient, or both, the patient has an MR-incompatible implant and/or another condition (e.g., claustrophobia) that would make it inadvisable for the subject to participate in MR imaging or any other study procedure. 6. The patient does not understand the informed consent information and/or the standard study instructions in spoken or written English, and/or is unable to follow study instructions. [The purpose of this exclusion criterion, required by the AU IRB, is to help ensure that the subjects adequately understand all the information relevant to providing informed consent, as well as the study instructions.] 7. Inability to give informed consent to participate in the study. 8. Pregnancy, as determined by a standard urine test for pregnancy. 9. Participation in other study/studies including an investigational drug or device during the present study.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Study-specific rehabilitation (SSR) procedures
Study-specific rehabilitation procedures will systematically manipulated the spatial or temporal synchrony (or coordination) of visual vs. haptic inputs that the subjects receive.

Locations

Country Name City State
United States Charlie Norwood VA Medical Center, Augusta, GA Augusta Georgia

Sponsors (2)

Lead Sponsor Collaborator
VA Office of Research and Development Augusta University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Accuracy of object recognition This outcome will be measured as the accuracy (% correct) with which the study subjects recognize the text objects before, during and after their participation in the study procedures. 6-10 weeks
Primary Response of brain regions of interest (ROI) as reflected in the BOLD (blood oxygenation level-dependent) response This outcome will be measured as changes (if any) of the BOLD responses of brain ROIs before, during and after their participation in the study procedures. 6-10 weeks
See also
  Status Clinical Trial Phase
Completed NCT01694680 - Intervention Trial in Early Age-related Macular Degeneration N/A
Completed NCT01224847 - Intravitreal Injection Anesthesia - Comparison of Different Topical Agents N/A
Withdrawn NCT04697953 - Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) Phase 3
Completed NCT05037396 - Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
Completed NCT00647439 - Genetics and Markers of Degenerative and Inflammatory Eye Diseases
Terminated NCT00902785 - A Study Of Early Markers Of Choroidal Neovascularization Phase 4
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Recruiting NCT03690505 - Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place N/A
Recruiting NCT03577041 - Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context
Completed NCT05082415 - Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
Completed NCT02445313 - Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
Recruiting NCT00354445 - A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD Phase 4
Completed NCT05111743 - Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
Terminated NCT02398500 - Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT05110209 - Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
Completed NCT05146687 - Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
Recruiting NCT04292080 - Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy Phase 2
Recruiting NCT03859245 - Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention N/A
Completed NCT02022540 - Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD Phase 1
Completed NCT02585401 - Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada N/A